Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$83.61 USD

83.61
5,456,718

+0.57 (0.69%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $83.61 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day

YETI, Gilead, Dick's, FedEx and Amazon highlighted as Zacks Bull and Bear of the Day

Madeleine Johnson headshot

Bear of the Day: Gilead Sciences (GILD)

The potential for revenue growth looks shaky for this biotech giant.

Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $65.75, moving +1.42% from the previous trading session.

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

Why Is Gilead (GILD) Down 4.9% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus

Intercept's (ICPT) Q4 revenues top estimates owing to strong Ocaliva sales, driven by sales force expansion and growth in its foreign geographies.

Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended

Nektar's (NKTR) earnings and sales beat estimates in the fourth quarter. The FDA extends the review period for NKTR-181 NDA by three months.

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More

Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.

Intercept Reports Positive Top-Line Data for NASH, Shares Up

Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.

Sanghamitra Saha headshot

Despite M&A Spree, Biotech ETFs Slide on Mixed Earnings

Biotech stocks came up with mixed earnings and weighed on the related ETFs in the key reporting season.

Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails

Gilead (GILD) suffers a setback as its phase III study on pipeline candidate, selonsertib, in patients with compensated cirrhosis (F4) due to NASH fails to meet goal.

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

Key highlights of the week were the fourth-quarter results by biotech bigwigs Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX) and Celgene (CELG).

UnitedHealth, MercadoLibre, Alphabet and Gilead highlighted as Zacks Bull and Bear of the Day

UnitedHealth, MercadoLibre, Alphabet and Gilead highlighted as Zacks Bull and Bear of the Day

Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat

A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.

Mark Vickery headshot

Alphabet (GOOGL) Outperforms Estimates, Gilead (GILD) Mixed

Google parent Alphabet posted Q4 earnings that came in stronger than expected, while Gilead's report was mixed with lower-than-expected earnings.

Gilead Sciences (GILD) Misses Q4 Earnings Estimates

Gilead (GILD) delivered earnings and revenue surprises of -15.29% and 4.81%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?

Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed the most recent trading day at $69.83, moving +0.34% from the previous trading session.

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanghamitra Saha headshot

What's Behind the Biotech ETF Rally to Start 2019?

Biotech ETFs have been riding on the wave of mergers and acquisitions as well as drug approvals.